MAGE-1161-169 peptide vaccine

MAGE-1161-169 peptide vaccine is a personalized peptide-based cancer vaccine intended for immunotherapy in patients with melanoma. It contains synthetic peptide sequences corresponding to the MAGE-1161-169 region, which is a fragment of a melanoma antigen gene (MAGE) commonly expressed in melanoma tumors. This vaccine is designed to stimulate an antigen-specific immune response—primarily cytotoxic T lymphocyte (CTL) activation—against tumor cells that present the MAGE peptide on their surface. The mechanism involves presentation of the MAGE-1161-169 peptide by major histocompatibility complex (MHC) molecules, resulting in immune recognition and destruction of melanoma cells[8]. Peptide vaccines such as this are typically used in combination with adjuvants (e.g., poly ICLC) and immune checkpoint inhibitors (e.g., nivolumab) to enhance anti-tumor immunity[1][2]. MAGE-1161-169 is an example of personalized neoantigen vaccine approaches tailored to individual tumor profiles in advanced melanoma.

Brand names

MAGE-1161-169 peptide vaccineMAGE1161-169 peptide vaccineMAGE 1161-169 peptide vaccine

Other names

MAGE-1161-169 peptide vaccineMAGE1161-169 peptide vaccineMAGE 1161-169 peptide vaccine